NSPR

InspireMD Inc

0.6990

Jul 02 • 04:00PM ET +0.0165 (2.42%)

Healthcare Medical Devices USA Nano NASD

Peers: ECOR LUNG ARAY BDMD LNSR POAS SERA MASS RXST TLSI

| Held by: IWC

Scroll to Statements

Index	-
Market Cap	32.74M
Enterprise Value	-5.72M
Income	-51.31M
Sales	10.85M
Book/sh	0.93
Cash/sh	0.89
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	127
IPO	Apr 11, 2011

P/E	-
Forward P/E	-
PEG	-
P/S	3.02
P/B	0.75
P/C	0.79
P/FCF	-
EV/EBITDA	-
EV/Sales	-0.53
Quick Ratio	4.82
Current Ratio	5.15
Debt/Eq	0.07
LT Debt/Eq	0.05
Option/Short	Yes / Yes

EPS (ttm)	-0.74
EPS next Y	-0.61
EPS next Q	-0.20
EPS this Y	2.63%
EPS next Y	17.57%
EPS next 5Y	-
EPS past 3/5Y	31.40% 35.83%
Sales past 3/5Y	20.19% 29.29%
EPS Y/Y TTM	7.25%
Sales Y/Y TTM	54.38%
EPS Q/Q	26.86%
Sales Q/Q	122.24%
Earnings	May 04 AMC
EPS/Sales Surpr.	11.11% 25.77%

Insider Own	28.65%
Insider Trans	1.30%
Inst Own	42.90%
Inst Trans	-1.41%
ROA	-107.86%
ROE	-142.60%
ROIC	-112.37%
Gross Margin	28.06%
Oper. Margin	-480.57%
Profit Margin	-472.98%
SMA20	-5.51%
SMA50	-26.74%
SMA200	-57.77%
Trades

Shs Outstand	46.84M
Shs Float	33.42M
Short Float	0.16%
Short Ratio	0.17
Short Interest	0.05M
52W High	2.93 -76.16%
52W Low	0.63 10.95%
Volatility	9.21% 11.36%
ATR (14)	0.08
RSI (14)	36.99
Beta	0.80
Rel Volume	0.51
Avg Volume	316.29K
Volume	160,103

Perf Week	6.72%
Perf Month	-30.79%
Perf Quarter	-55.48%
Perf Half Y	-63.02%
Perf YTD	-60.73%
Perf Year	-68.65%
Perf 3Y	-72.15%
Perf 5Y	-85.45%
Perf 10Y	-100.00%
Recom	1.00
Target Price	3.67
Prev Close	0.68
Price	0.70
Change	2.42%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-02-26	Initiated	Maxim Group	Buy	$6
Jan-07-16	Initiated	Rodman & Renshaw	Buy	$4
Mar-13-15	Downgrade	Oppenheimer	Outperform → Perform
Nov-26-13	Initiated	Oppenheimer	Outperform	$6

Jun-12-26 04:05PM	InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-11-26 08:00AM	InspireMD Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR Procedures (GlobeNewswire) -5.95%
Jun-08-26 08:00AM	InspireMD Announces First Patient Enrolled in the CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System for Use in TCAR Procedures (GlobeNewswire) -7.24%
May-06-26 04:05PM	InspireMD to Participate in Upcoming Bank of America Securities 2026 Global Healthcare Conference (GlobeNewswire) +5.45%
May-05-26 08:30AM	InspireMD, Inc. Q1 2026 Earnings Call Summary (Moby) -5.98%
04:05PM	Loading…
May-04-26 04:05PM	InspireMD Reports First Quarter 2026 Financial Results (GlobeNewswire)
May-01-26 04:05PM	InspireMD Initiates Voluntary U.S. Recall of CGuard Prime 135 cm Carotid Stent Delivery System (GlobeNewswire)
04:05PM	InspireMD Announces FDA Approval of Investigational Device Exemption Application for CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System (GlobeNewswire)
Apr-27-26 04:05PM	InspireMD to Announce First Quarter 2026 Financial Results (GlobeNewswire) -5.79%
Apr-08-26 08:01PM	After Plunging 15.2% in 4 Weeks, Here's Why the Trend Might Reverse for InspireMD (NSPR) (Quartz)
Mar-31-26 04:05PM	InspireMD to Participate in Upcoming 25th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-18-26 03:02PM	InspireMD Inc (NSPR) Q4 2025 Earnings Call Highlights: Revenue Surge and Strategic Advancements (GuruFocus.com)
07:00AM	InspireMD Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Mar-09-26 05:10PM	Stereotaxis Inc. (STXS) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
09:00AM	InspireMD to Announce Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
05:35PM	Loading…
Mar-03-26 05:35PM	NeuroPace, Inc. (NPCE) Reports Q4 Loss, Beats Revenue Estimates (Zacks) -7.10% -5.29%
Feb-25-26 04:15PM	Penumbra (PEN) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
Jan-20-26 09:00AM	InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-12-26 09:00AM	InspireMD Announces Publication of the C-GUARDIANS Pivotal Trial Manuscript in the Journal of the American College of Cardiology (JACC) (GlobeNewswire) -5.81%
Nov-24-25 07:30AM	Landmark CREST-2 Study Published in the New England Journal of Medicine Highlights the Benefits of Carotid Artery Stenting (GlobeNewswire)
Nov-21-25 09:00AM	InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +13.53%
Nov-19-25 04:42PM	InspireMD to Participate in Upcoming Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire) -11.46%
Nov-04-25 04:06PM	InspireMD Inc (NSPR) Q3 2025 Earnings Call Highlights: Robust Revenue Growth Amid Rising Expenses (GuruFocus.com) -7.21%
08:15AM	InspireMD, Inc. (NSPR) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	InspireMD Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-03-25 05:15PM	Hologic (HOLX) Q4 Earnings and Revenues Beat Estimates (Zacks)
07:30AM	InspireMD Names Peter A. Soukas, M.D., as Chief Medical Officer (GlobeNewswire)
Oct-21-25 06:20PM	Intuitive Surgical, Inc. (ISRG) Q3 Earnings and Revenues Top Estimates (Zacks)
04:05PM	InspireMD to Announce Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-08-25 08:00AM	InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04:05PM	Loading…
Sep-25-25 04:05PM	InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-21-25 09:06PM	Parkman Healthcare Expands Stake in InspireMD Backing Carotid Innovation (Insider Monkey)
Sep-17-25 08:00AM	InspireMD Announces the Appointment of Dan Dearen to its Board of Directors (GlobeNewswire)
Aug-27-25 09:00AM	InspireMD to Present at Upcoming H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-05-25 08:00AM	InspireMD Reports Second Quarter 2025 Financial Results (GlobeNewswire) -8.24%
Aug-04-25 10:12AM	What to Expect from InspireMD Inc (NSPR) Q2 2025 Earnings (GuruFocus.com)
08:05AM	RxSight, Inc. Appoints Raymond W. Cohen to Its Board of Directors (GlobeNewswire)
Jul-31-25 08:31AM	InspireMD Announces the Appointment of Raymond W. Cohen to its Board of Directors (GlobeNewswire) +17.72%
08:30AM	InspireMD Announces Combined Financings of $58 Million (GlobeNewswire)
Jul-22-25 07:00AM	InspireMD to Announce Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-17-25 04:58AM	CVRx (CVRX) Surges 19.0%: Is This an Indication of Further Gains? (Zacks)
Jul-11-25 09:57AM	InspireMD Launches CGuard Prime Carotid Stent System in the U.S. (Zacks)
Jul-09-25 07:00AM	InspireMD Announces U.S. Commercial Launch of CGuard Prime Carotid Stent System for the Prevention of Stroke (GlobeNewswire) +7.52%
Jun-24-25 04:05PM	InspireMD Announces FDA Approval for CGuard Prime Carotid Stent System for the Prevention of Stroke (GlobeNewswire) -9.49%
Jun-13-25 09:00AM	InspireMD Announces CE Mark Approval for CGuard Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke (GlobeNewswire) -7.20%
Jun-03-25 04:05PM	InspireMD Announces Appointment of Michael Lawless as Chief Financial Officer (GlobeNewswire)
May-10-25 03:04AM	InspireMD Inc (NSPR) Q1 2025 Earnings Call Highlights: Revenue Growth Amid Operational Challenges (GuruFocus.com)
May-09-25 08:15AM	InspireMD, Inc. (NSPR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:00AM	InspireMD Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-08-25 05:45PM	Globus Medical (GMED) Lags Q1 Earnings and Revenue Estimates (Zacks)
09:49AM	InspireMD Inc (NSPR) Q1 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
May-06-25 08:10AM	IQVIA Holdings (IQV) Surpasses Q1 Earnings and Revenue Estimates (Zacks)
Apr-30-25 09:00AM	InspireMD to Present at Upcoming Bank of America 2025 Healthcare Conference (GlobeNewswire)
Apr-25-25 09:00AM	InspireMD to Announce First Quarter 2025 Financial Results (GlobeNewswire)
Apr-08-25 09:00AM	InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-26-25 09:00AM	InspireMD to Present at Upcoming 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-13-25 03:04AM	InspireMD Inc (NSPR) Q4 2024 Earnings Call Highlights: Revenue Growth Amid Rising Expenses and ... (GuruFocus.com)
Mar-12-25 07:00AM	InspireMD Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-26-25 08:00AM	InspireMD to Announce Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-25-25 08:00AM	InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.11%
Feb-13-25 07:00AM	InspireMD and NAMSA to Partner on CGUARDIANS II Pivotal Clinical Trial of the CGuard Prime 80 cm Carotid Stent System for Use in TCAR procedures (GlobeNewswire)
Feb-04-25 07:00AM	InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.20%
Jan-21-25 07:00AM	InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.92%
Dec-12-24 07:00AM	InspireMD Announces Expected Retirement of its CFO Craig Shore and CFO Transition in 2025 (GlobeNewswire)
Dec-09-24 07:00AM	InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR) (GlobeNewswire)
Nov-25-24 04:05PM	InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors (GlobeNewswire) +10.94%
Nov-13-24 02:09AM	InspireMD Inc (NSPR) Q3 2024 Earnings Call Highlights: Revenue Growth Amid Rising Costs and ... (GuruFocus.com) +5.24%
Nov-12-24 07:00AM	InspireMD Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-11-24 07:25AM	What To Expect From InspireMD Inc (NSPR) Q3 2024 Earnings (GuruFocus.com) +7.68%
Nov-08-24 05:30PM	InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-04-24 08:00AM	InspireMD to Report Third Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, November 12th (GlobeNewswire)
Oct-15-24 07:00AM	InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System (GlobeNewswire) -5.66%
Oct-08-24 07:28AM	InspireMD Advances with FDA Study Approval and Global Goals (TipRanks)
Oct-07-24 07:00AM	InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System (GlobeNewswire)
Sep-16-24 07:00AM	InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard Prime Carotid Stent System (GlobeNewswire)
Aug-06-24 08:09AM	InspireMD Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Aug-05-24 07:00AM	InspireMD Congratulates CREST-2 Investigators on Completion of Trial Enrollment (GlobeNewswire)
Jul-30-24 07:00AM	InspireMD to Report Second Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, August 6th (GlobeNewswire) -16.87%
Jul-01-24 07:00AM	InspireMD Announces Full Exercise of Series H Warrant Tranche for Gross Proceeds of $17.9 Million (GlobeNewswire)
May-28-24 08:53AM	InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024 (GlobeNewswire)
May-14-24 10:53AM	NSPR Stock Earnings: InspireMD Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
07:00AM	InspireMD Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-07-24 07:00AM	InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th (GlobeNewswire)
Apr-03-24 08:59AM	InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-26-24 07:00AM	InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024 (GlobeNewswire)
Mar-07-24 10:09AM	InspireMD, Inc. (NASDAQ:NSPR) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-06-24 12:53PM	NSPR Stock Earnings: InspireMD Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
07:00AM	InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-28-24 07:00AM	InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th (GlobeNewswire)
Feb-12-24 07:00AM	InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard Neuroprotection System (GlobeNewswire)
Feb-05-24 11:27AM	InspireMD's (NSPR) CE Mark Recertification to Boost CGuard EPS (Zacks)
Jan-31-24 07:00AM	InspireMD Receives CE Mark Recertification Under EU's New Medical Device Regulation (MDR) Regulatory Framework (GlobeNewswire)
Jan-03-24 07:00AM	InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America (GlobeNewswire)
Dec-20-23 07:00AM	InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard Neuroprotection System (GlobeNewswire) -5.50%
Nov-27-23 07:00AM	InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions (GlobeNewswire) +6.41%
Nov-07-23 09:12AM	InspireMD, Inc. (NASDAQ:NSPR) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-06-23 08:11AM	InspireMD Inc (NSPR) Reports Q3 2023 Financial Results: CGuard EPS Revenue Increases by 9% ... (GuruFocus.com)
07:00AM	InspireMD Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-02-23 08:00AM	InspireMD to Participate in Upcoming November Investor Conferences (GlobeNewswire) -11.41%
Nov-01-23 02:19PM	InspireMD Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial at VIVA23 (GlobeNewswire) +11.21%

InspireMD, Inc. is medical device company, which engages in the development and commercialization of its proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. Its products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction and saphenous vein graft coronary interventions. The company was founded in 2005 and is headquartered in Miami, FL.

PresidentMr. Marvin L. Slosman

CFOMr. Michael A. Lawless

Chief Commercial OfficerMr. Shane Thomas Gleason

Vice President of Human Resources & Organizational DevelopmentMs. Donna DeChant

Executive VP of Finance & Regional ManagerMr. Amir Kohen

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Stuka Paul	Director	May 27 '26	Buy	0.88	20,000	17,500	667,871	May 29 04:05 PM
Gleason Shane Thomas	Chief Commercial Officer	May 19 '26	Sale	1.01	22,778	23,006	1,053,882	May 21 05:16 PM
Gleason Shane Thomas	Chief Commercial Officer	Feb 02 '26	Sale	1.59	2,941	4,676	1,076,660	May 21 05:16 PM
Stuka Paul	Director	May 13 '26	Buy	1.16	10,000	11,575	642,871	May 15 04:05 PM
Stuka Paul	Director	May 14 '26	Buy	1.15	5,000	5,750	647,871	May 15 04:05 PM
Slosman Marvin	CEO and President	May 12 '26	Buy	1.20	21,000	25,200	3,556,658	May 13 05:00 PM
Stuka Paul	Director	May 08 '26	Buy	1.16	65,626	76,126	622,871	May 12 07:35 PM
Stuka Paul	Director	May 11 '26	Buy	1.19	10,000	11,900	632,871	May 12 07:35 PM
Ward Scott R.	Director	May 07 '26	Buy	1.15	73,255	84,243	237,096	May 08 05:08 PM
Ward Scott R.	Director	May 06 '26	Buy	1.15	15,995	18,394	163,841	May 08 05:08 PM
Stuka Paul	Director	May 07 '26	Buy	1.15	6,378	7,335	531,599	May 08 05:05 PM
Stuka Paul	Director	May 06 '26	Buy	1.12	1,517	1,699	525,221	May 08 05:05 PM
ROUBIN GARY S	Director	May 07 '26	Buy	1.18	90,000	106,200	834,478	May 08 05:03 PM
Gleason Shane Thomas	Chief Commercial Officer	Jan 21 '26	Sale	1.62	17,593	28,553	1,174,664	Feb 02 05:01 PM
Gleason Shane Thomas	Chief Commercial Officer	Jan 28 '26	Sale	1.65	12,395	20,464	1,149,077	Feb 02 05:01 PM
Gleason Shane Thomas	Chief Commercial Officer	Jan 22 '26	Sale	1.57	8,411	13,239	1,166,253	Feb 02 05:01 PM
Gleason Shane Thomas	Chief Commercial Officer	Jan 29 '26	Sale	1.65	5,000	8,250	1,144,077	Feb 02 05:01 PM
Gleason Shane Thomas	Chief Commercial Officer	Jan 27 '26	Sale	1.66	4,781	7,956	1,161,472	Feb 02 05:01 PM
Gleason Shane Thomas	Chief Commercial Officer	Jan 30 '26	Sale	1.63	2,900	4,730	1,141,177	Feb 02 05:01 PM
Gleason Shane Thomas	Chief Commercial Officer	Jan 20 '26	Sale	1.59	2,955	4,710	1,192,257	Feb 02 05:01 PM
Gleason Shane Thomas	Chief Commercial Officer	Jan 15 '26	Sale	1.58	2,909	4,593	1,197,462	Feb 02 05:01 PM
Gleason Shane Thomas	Chief Commercial Officer	Jan 16 '26	Sale	1.61	2,250	3,627	1,195,212	Feb 02 05:01 PM
Gleason Shane Thomas	Chief Commercial Officer	Feb 02 '26	Sale	1.60	2,000	3,208	1,139,177	Feb 02 05:01 PM
Stuka Paul	Director	Dec 09 '25	Buy	1.81	5,073	9,182	391,628	Dec 11 04:05 PM
Stuka Paul	Director	Dec 05 '25	Buy	1.86	5,073	9,436	388,918	Dec 08 04:05 PM
Stuka Paul	Director	Dec 04 '25	Buy	1.85	10,130	18,740	383,845	Dec 05 04:05 PM
Stuka Paul	Director	Nov 12 '25	Buy	1.62	13,431	21,758	373,715	Nov 13 04:05 PM
ROUBIN GARY S	Director	Jul 30 '25	Buy	2.42	41,322	99,999	608,425	Aug 01 05:00 PM
Kester Thomas J	Director	Jul 30 '25	Buy	2.42	30,991	74,998	420,758	Aug 01 05:00 PM
Slosman Marvin	CEO and President	Jul 30 '25	Buy	2.42	10,330	24,999	2,420,866	Aug 01 05:00 PM
Stuka Paul	Director	Jul 30 '25	Buy	2.42	20,661	50,000	444,195	Aug 01 05:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

$100 Off Your First Year Get Elite For Just $199.50

NSPR

InspireMD Inc

Upgrade your Finviz experience